These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8588236)

  • 61. The use of cyclosporine in renal transplantation.
    Hesselink DA; Smak Gregoor PJ; Weimar W
    Transplant Proc; 2004 Mar; 36(2 Suppl):99S-106S. PubMed ID: 15041316
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Monitoring of nuclear factor of activated T-cell-regulated gene expression in de novo and long-term liver transplant recipients treated with cyclosporine a.
    Herden U; Kromminga A; Hagel C; Hartleb J; Nashan B; Sterneck M; Fischer L
    Ther Drug Monit; 2011 Apr; 33(2):185-91. PubMed ID: 21383649
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The evolution of therapeutic drug monitoring of cyclosporine.
    Kahan BD
    Transplant Proc; 2001; 33(7-8):3086-8. PubMed ID: 11750326
    [No Abstract]   [Full Text] [Related]  

  • 64. Cyclosporine: from renal transplantation to autoimmune diseases.
    Ponticelli C
    Ann N Y Acad Sci; 2005 Jun; 1051():551-8. PubMed ID: 16126995
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Current opinions on therapeutic drug monitoring of immunosuppressive drugs.
    Shaw LM; Holt DW; Keown P; Venkataramanan R; Yatscoff RW
    Clin Ther; 1999 Oct; 21(10):1632-52; discussion 1631. PubMed ID: 10566561
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs.
    Zhang Y; Zhang R
    Drug Test Anal; 2018 Jan; 10(1):81-94. PubMed ID: 28851030
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A.
    Bauer S; Brockmöller J; Kewitz H; Roots I
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):540-2. PubMed ID: 1283385
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A randomized, prospective, double-blinded trial of cyclosporine vs. OG37-325 in cadaveric renal transplantation--a preliminary report.
    Henry ML; Tesi RJ; Elkhammas EA; Ferguson RM
    Transplantation; 1993 Apr; 55(4):748-51; discussion 751-2. PubMed ID: 8475547
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacodynamic monitoring of immunosuppressive drugs.
    Yatscoff RW; Aspeslet LJ; Gallant HL
    Clin Chem; 1998 Feb; 44(2):428-32. PubMed ID: 9474055
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
    Ray JE; Keogh AM; McLachlan AJ
    J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The impact of cyclosporin formulation on clinical outcomes.
    Holt DW; Johnston A
    Transplant Proc; 2000 Nov; 32(7):1552-5. PubMed ID: 11119831
    [No Abstract]   [Full Text] [Related]  

  • 72. Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients.
    Sud K; Singh B; Krishna VS; Thennarasu K; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Nephrol Dial Transplant; 1999 Jul; 14(7):1698-703. PubMed ID: 10435879
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics of cyclosporine G in patients with renal failure.
    Wenk M; Bindschedler M; Costa E; Zuber M; Vozeh S; Thiel G; Abisch E; Keller HP; Beveridge T; Follath F
    Transplantation; 1988 Mar; 45(3):558-61. PubMed ID: 3347936
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus.
    Naeyaert JM; Lachapelle JM; Degreef H; de la Brassinne M; Heenen M; Lambert J
    Dermatology; 1999; 198(2):145-52. PubMed ID: 10325461
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients.
    Barten MJ; Rahmel A; Garbade J; Bold A; Bittner HB; Dhein S; Mohr FW; Gummert JF
    Transplant Proc; 2005 Dec; 37(10):4532-4. PubMed ID: 16387162
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone.
    Fox RI; Morgan SL; Smith HT; Robbins BA; Choc MG; Baggott JE
    Rheumatology (Oxford); 2003 Aug; 42(8):989-94. PubMed ID: 12730515
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
    Singh D; Kiberd B; Belitsky P; Fraser A; Balbontin F; Lawen J
    Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Use of cyclosporin-A in experimental spinal cord injury: design of a dosing strategy to maintain therapeutic levels.
    Ibarra A; Reyes J; Martínez S; Correa D; Guízar-Sahagún G; Grijalva I; Castañeda-Hernández G; Flores-Murrieta FJ; Franco-Bourland R; Madrazo I
    J Neurotrauma; 1996 Oct; 13(10):569-72. PubMed ID: 8915908
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The CARI guidelines. Calcineurin inhibitors in renal transplantation: therapeutic drug monitoring.
    Trevillian P;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S57-65. PubMed ID: 17316283
    [No Abstract]   [Full Text] [Related]  

  • 80. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
    Chiodini B; Bassan R; Barbui T
    Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.